Literature DB >> 20107143

Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics.

Danielle Wolvers1, Jean-Michel Antoine, Eveliina Myllyluoma, Juergen Schrezenmeir, Hania Szajewska, Ger T Rijkers.   

Abstract

The rationale for the use of probiotics in the management of infectious diseases is supported by their potential to influence and stabilize the composition of gut microbiota, enhance colonization resistance, and modulate immune function parameters. A literature review was conducted to determine the efficacy of using probiotics in selected infections: 1) infectious diarrhea in infants and children, 2) traveler's diarrhea, 3) necrotizing enterocolitis in infants, 4) Helicobacter pylori infection, 5) respiratory tract infections in adults and children, 6) ear, nose, and throat infections, and 7) infectious complications in surgical and critically ill patients. The different types of infections that have been subject to clinical studies with different probiotics obviously prevent any generic conclusions. Furthermore, the lack of consistency among studies focusing on 1 specific infection, in study design, applied probiotic strains, outcome parameters, and study population, along with the still limited number of studies, preclude clear and definite conclusions on the efficacy of probiotics and illustrate the need for better-aligned study designs and methodology. Exceptions were the management of infectious diarrhea in infants and traveler's diarrhea, antibiotic-associated diarrhea, and necrotizing enterocolitis. Sufficient consistent data exist for these applications to conclude that certain probiotics, under certain conditions, and in certain target populations, are beneficial in reducing the risk of infection. In addition, some evidence exists, although conclusions are premature, for the management of Helicobacter pylori infection and possible reduction of treatment side effects. Certain probiotics may also reduce the risk of various symptoms of respiratory tract infections in adults and children, including ear, nose, and throat infections, although data are currently far too limited to distill any clinical recommendations in this area. Positive but also negative results have been obtained in prevention of infectious complications in surgical and critically ill patients. For future studies it is recommended that researchers provide adequate power, identify pathogens, and report both clinical outcomes and immune biomarkers relating to putative underlying mechanisms.

Entities:  

Mesh:

Year:  2010        PMID: 20107143     DOI: 10.3945/jn.109.113753

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  40 in total

Review 1.  Dysbiosis and the immune system.

Authors:  Maayan Levy; Aleksandra A Kolodziejczyk; Christoph A Thaiss; Eran Elinav
Journal:  Nat Rev Immunol       Date:  2017-03-06       Impact factor: 53.106

Review 2.  Microbiota restoration: natural and supplemented recovery of human microbial communities.

Authors:  Gregor Reid; Jessica A Younes; Henny C Van der Mei; Gregory B Gloor; Rob Knight; Henk J Busscher
Journal:  Nat Rev Microbiol       Date:  2010-11-29       Impact factor: 60.633

3.  Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics.

Authors:  Theo S Plantinga; Wendy W C van Maren; Jeroen van Bergenhenegouwen; Marjolijn Hameetman; Stefan Nierkens; Cor Jacobs; Dirk J de Jong; Leo A B Joosten; Belinda van't Land; Johan Garssen; Gosse J Adema; Mihai G Netea
Journal:  Clin Vaccine Immunol       Date:  2011-02-02

4.  The Effect of Synbiotic Supplementation on Growth Parameters in Mild to Moderate FTT Children Aged 2-5 Years.

Authors:  Majid Aflatoonian; Abbas Taghavi Ardakani; Seyedeh Zalfa Modarresi; Vajiheh Modaresi; Mehran Karimi; Mahtab Ordooei; Mahmood Vakili; Bahar Pakseresht
Journal:  Probiotics Antimicrob Proteins       Date:  2020-03       Impact factor: 4.609

Review 5.  Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease.

Authors:  Collin L Ellis; John C Rutledge; Mark A Underwood
Journal:  Gut Microbes       Date:  2010 Nov-Dec

Review 6.  Actual concept of "probiotics": is it more functional to science or business?

Authors:  Michele Caselli; Francesca Cassol; Girolamo Calò; John Holton; Giovanni Zuliani; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

7.  In vivo gut transcriptome responses to Lactobacillus rhamnosus GG and Lactobacillus acidophilus in neonatal gnotobiotic piglets.

Authors:  Anand Kumar; Anastasia N Vlasova; Zhe Liu; Kuldeep S Chattha; Sukumar Kandasamy; Malak Esseili; Xiaoli Zhang; Gireesh Rajashekara; Linda J Saif
Journal:  Gut Microbes       Date:  2014-01-22

8.  Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial.

Authors:  Lee E Morrow; Marin H Kollef; Thomas B Casale
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

Review 9.  Novel perspectives on therapeutic modulation of the gut microbiota.

Authors:  Justin L McCarville; Alberto Caminero; Elena F Verdu
Journal:  Therap Adv Gastroenterol       Date:  2016-04-04       Impact factor: 4.409

Review 10.  Gut microbiome, gut function, and probiotics: Implications for health.

Authors:  Neerja Hajela; B S Ramakrishna; G Balakrish Nair; Philip Abraham; Sarath Gopalan; Nirmal K Ganguly
Journal:  Indian J Gastroenterol       Date:  2015-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.